Backgrounds/Aims: Mycophenolate mofetil (MMF) has wide inter-and intra-individual variability of mycophenolic acid (MPA) after liver transplantation (LT). On this study, we aimed to analyse the intra-individual variability of MPA concentration in stable adult LT recipients receiving MMF monotherapy and develop a method to determine the target level in the situation of wide intra-individual variability. Methods: This retrospective cross-sectional study included 30 LT recipients. All patients received MMF monotherapy at a dose of 500 mg twice daily for ≥2 years and were divided into two groups based on renal function. MPA concentration-associated values were presented as mean with standard deviation and coefficient of variation (CV). Results: The normal renal function group (n=15) showed a mean 12-hour MPA concentration of 2.5±0.5 g/ml (range, 1.8±0.5 to 3.6±0.7 g/ml) and a mean CV of 20.4±7.7% (range, 8.7% to 39.4%). In the renal dysfunction group (n=15), the 12-hour MPA concentration fluctuated more widely with a mean value of 3.7±0.9 g/ml (range, 2.8±0.8 to 5.1±1.2 g/ml) and a mean CV of 24.5±4.9% (range, 17.1% to 37.5%). The 12-hour MPA concentration was significantly higher in the renal dysfunction group, as compared to the normal renal function group (p=0.001); whereas, the CV was not significantly different between the two groups (p=0.093).
INTRODUCTION
Mycophenolate mofetil (MMF) is commonly administered after liver transplantation (LT) because of the lack of nephrotoxic effects unlike the calcineurin inhibitor (CNI). [1] [2] [3] Mycophenolic acid (MPA), the pharmacokinetically active product of MMF, has potent inhibitory effects on lymphocyte proliferation. MPA is taken up by the liver, where it is glucuronidated to form an inactive compound. MPA metabolites are primarily eliminated by the kidneys. 4, 5 Thus, the blood level and clearance of MPA is greatly influenced by renal function.
MMF has been regarded as a categorically-dosed drug probably due to the wide inter-and intra-individual variability of the blood concentration as well as lack of information on clinician-oriented pharmacokinetics. 6 Few clinical studies on the relationship between potency and drug concentration have been conducted previously. As a result, MMF has been administered on the basis of personal or institutional experience, without generalized guidelines to perform therapeutic drug monitoring (TDM)
for dosage adjustment. Moreover, the wide intra-individual variability of MPA level has been ignored in the clinical setting due to lack of specific knowledge.
Decline in renal function results in significant impairment of the clearance of MPA metabolites, with the con-sequent increase in blood concentrations of MPA metabolites and augmented immunosuppression. 7 Thus, in patients with renal dysfunction, special attention to the MPA pharmacokinetics is required on administration of MMF as the main immunosuppressant. We previously reported that it is necessary to adjust the MMF dosage on an individualized basis based on the results of MPA TDM, particularly for patients with markedly impaired renal function. Based on our experience, patients with renal dysfunction often showed a wide range of variability in the trough MPA concentration; thus, analysis of the pattern of variability in MPA concentration is required.
The primary goal of the present study was to analyse the intra-individual variability of MPA concentration in stable adult LT recipients receiving MMF monotherapy;
and the secondary goal was to develop a method to determine the target TDM level in the situation of wide intra-individual variability.
MATERIALS AND METHODS

Study design
This study was performed as a retrospective cross-sec- 
Patient selection
From our institutional LT database of over 5000 patients, 30 adult LT recipients were selected for inclusion in the study. All selected patents were stable in liver function and had been treated with MMF monotherapy at a daily dose of 1000 mg (500 mg twice per day) for ≥2
years, primarily because they were not able to tolerate CNI-associated nephrotoxicity. Patients who showed any type of graft dysfunction during the study period were excluded from study. Patients receiving different doses of MMF in the morning and evening (e.g., 500 mg plus 750 mg per day) as well as daily administration of MMF ≥1500 mg were excluded from the analysis of 12-hour MPA TDM. Most of the study patients were in the ≥5 years post-LT, hence, the target MPA level was set at 2-3 ng/ml.
In addition, we selected the patients based on serum creatinine levels as the normal renal function group (normal group: mean serum creatinine ≤1.4 mg/dl; n=15) and the renal dysfunction group (dysfunction group: mean serum creatinine 2.0-2.9 mg/dl; n=15). The clinical profiles of patients in these two study groups were adjusted by propensity score matching. None of the patients in the renal dysfunction group underwent hemodialysis during the cross-sectional study period.
The detailed MMF immunosuppression profiles have been described previously. 6, 8 Pre-dose 12-hour blood samples were subjected to MPA TDM using an enzyme multi- 
RESULTS
Patient profiles
The primary causes of LT in the 30 study patients were hepatitis B virus-associated liver cirrhosis (n=22), alco- 
Variability of 12-hour MPA concentration in patients with renal dysfunction
The 12-hour MPA concentration showed more fluctuation periodically in nearly all of patients in the renal dysfunction group (n=15), as compared to the normal renal function group (Fig. 2) . The 12-month mean value with SD of 12-hour MPA concentration in each patient ranged from 2.8±0.8 g/ml to 5.1±1.2 g/ml at the mean serum creatinine level of between 2.0 mg/dl and 2.9 mg/dl. The Comparison of mean and variability of 12-hour MPA concentration according to renal function The 12-hour MPA concentrations in the normal and renal dysfunction groups were compared in terms of the mean value (p=0.001) and CV (p=0.093) (Fig. 3) . were presented in literature. [14] [15] [16] [17] [18] In contrast, a prospective randomised trial of MMF monotherapy did not present any episodes of acute rejection during 5 years of the fol-low-up study period. 19 In this study, the primary study goal was focused on the intra-individual variability of MPA concentration. In patients with normal renal function, the mean of individual CV value of 12-hour MPA concentration was 2.5±0.5 g/ml with 20.4±7.7% of CV value, which was lower than expected. In studies with renal transplantation, high inter-individual variability of tacrolimus was reportedly associated with a higher incidence of acute rejection. 9, 10 In contrast, in patients with renal dysfunction, In conclusion, the results of this study provided the detailed information on inter-and intra-individual variability of 12-hour MPA concentration. MPA TDM is necessary to reasonably cope with the inter-individual and intra-individual variability of MMF pharmacokinetics in LT recipients.
DISCUSSION
